Speakers

Expand/Collapse

Charlotte Price
Manager, Small Molecules
Beacon Targeted Therapies

Day One

Tuesday January 25 2021

8:10 am | Three Generations of DDR Therapeutics - Where Are We Now

Stephen Pettitt
Senior Researcher
Institute of Cancer Research

Sharon B. Cantor
Professor, Department of Molecular, Cell and Cancer Biology
University of Massachusetts Medical School

Sylvie Sauvaigo
President & Chief Scientific Officer
LXRepair

Day One

Tuesday January 25 2021

11:50 am | A New Dimension in Precision Oncology with the SPOT-LX DNA Repair Testing Platform

Mads Daugaard
President & Chief Scientific Officer
Rakovina Therapeutics

Day One

Tuesday January 25 2021

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Matthew Robers
Senior Research Scientist & Group Leader
Promega

Day One

Tuesday January 25 2021

2:50 pm | Exploring the Landscape of PARP Inhibitor Selectivity in Cells with NanoBRET

Claudio Sturino
Senior Director, Head of Chemistry & Pharmaceutical Development
adMare Bioinnovations

Day Two

Wednesday, January 26 2022

1:00 pm | Discovery of a Potent, Selective, Bio-Available & Highly Efficacious DNAPK Inhibitor

Kirsten Timms
Vice President, Biomarker Discovery
Myriad Genetics

Day One

Tuesday January 25 2021

1:00 pm | Talk Title to be Announced

C. Gary Marshall
Senior Director of Project Leadership
Repare Therapeutics

Day Two

Wednesday, January 26 2022

2:30 pm | Progress in PKMYT1 Inhibition: RP-6306

Shikang Liang
Postdoctoral Research Scientist, Blundell Group, Department of Biochemistry
University of Cambridge

Day Two

Wednesday, January 26 2022

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

Michal Zimmermann
Associate Director of Cancer Biology
Repare Therapeutics

Day Two

Wednesday, January 26 2022

9:00 am | ATRi Development & Biomarker-Led Selection; Bridging the Gap Between the Lab & the Clinic

Kalindi Parmar
Associate Director, Center for DNA Damage & Repair
Harvard Medical School Dana- Farber Cancer Institute

Day One

Tuesday January 25 2021

4:30 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Speaker TBC

Tempus Labs

Day One

Tuesday January 25 2021

3:30 pm | Talk Title to be Announced

Andrew Wylie
Senior Vice President & Head of Oncology
KSQ Therapeutics

Day Two

Wednesday, January 26 2022

12:30 pm | Exploring KSQ-4279, a First in Class USP1 Inhibitor for the Treatment of Tumors with Defects in DNA Damage Repair

Nathalie Agar
Director of Surgical Molecular Imaging, Laboratory & Department of Neurosurgery
Brigham & Women’s Hospital Department of Cancer Biology Dana-Farber Cancer Institute

Day One

Tuesday January 25 2021

4:30 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Timothy Yap
Associate Professor, Investigational Cancer Therapeutics
MD Anderson Cancer Center

Day One

Tuesday January 25 2021

2:20 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

Day Two

Wednesday, January 26 2022

5:30 pm | Closing Panel Discussion: Future Directions for DDRi

5:00 pm | Targeting ATR in the Clinic: Novel Agents and Rational Combinations

Geoffrey Shapiro
Professor, Medicine, Harvard Medical School, Director of Early Drug Development Center
Dana-Farber Cancer Institute

Day One

Tuesday January 25 2021

4:30 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Caroline Ben
Chief Scientific Officer & Co- Founder
LoQus23 Therapeutics

Ioannis Gounaris
Senior Medical Director Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II
Merck KGaA

Day Two

Wednesday, January 26 2022

8:30 am | ATR Inhibitor-Based Combination Treatments in the Clinic: Biomarkers for Patient Selection

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

Frank Zenke
Global Head DNA Damage Response Research
Merck KGaA

Day One

Tuesday January 25 2021

2:20 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

10:00 am | Preclinical & Clinical Exploration of ATR Inhibitors

John Pascal
Professor of Biochemistry & Molecular Medicine
University of Montreal

Oren Gilad
Chief Executive Officer
Atrin Pharmaceuticals

Day One

Tuesday January 25 2021

2:20 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

11:20 am | Progress in ATR & WEE1 Inhibitors: As Single Agents & Synergy in Combination Therapy

Debanu Das
Chief Executive Officer
XPose Therapeutics

Day One

Tuesday January 25 2021

3:00 pm | Screening & Best Assays for Compound Optimization: Quick SAR By X-Ray Poses

Monah Abed
Principal Scientist
IDEAYA Biosciences

Day Two

Wednesday, January 26 2022

12:00 pm | Developing a PARG Inhibitor

Sui Xiong Cai
Executive Vice President & Chief Technology Officer
IMPACT Therapeutics

Day One

Tuesday January 25 2021

2:20 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

Mark O’Connor
Chief Scientist Oncology, Head of the DDR Strategic Biology Area
AstraZeneca

Day One

Tuesday January 25 2021

12:30 pm | Targeting Replication Stress in Cancers with Adavosertib, the First in Class WEE1 Inhibitor

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Day Two

Wednesday, January 26 2022

5:30 pm | Closing Panel Discussion: Future Directions for DDRi

Ranjit Bindra
Professor, Departments of Therapeutic Radiology & Pathology
Yale School of Medicine

Day One

Tuesday January 25 2021

4:30 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Day Two

Wednesday, January 26 2022

5:30 pm | Closing Panel Discussion: Future Directions for DDRi

Peter Huang
Senior Vice President Discovery
Zentalis Pharmaceuticals

Day One

Tuesday January 25 2021

12:00 pm | Discovery & Progress of ZN-c3, a Highly Potent & Selective WEE1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

Elisabetta Leo
Principal Scientist - Associate Director
AstraZeneca

Day One

Tuesday January 25 2021

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

8:30 am | Progress in PARP1 Selective Inhibitors: AZD5305

Kent Mouw
Assistant Professor of Radiation Oncology
Dana-Farber Cancer Institute

Day Two

Wednesday, January 26 2022

1:10 pm | Emerging Roles of the ATR/CHK1 Axis in Nucleotide Excision Repair

Nicola Curtin
Experimental Therapeutics Professor
Newcastle University

Day Two

Wednesday, January 26 2022

3:00 pm | Durability of PARP Inhibition: Implications for Dose & Schedule as Single Agent & Combination Therapy

Helen Robinson
Vice President of Biology
Artios Pharma

Day One

Tuesday January 25 2021

5:00 pm | Exploring Polθ as a New DDR Target

Alan D’Andrea
Director: Center for DNA Damage and Repair, Director
Susan F. Smith Center for Women’s Cancers (SFSCWC) Professor Harvard Medical School Dana-Farber Cancer Institute

Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society

Day One

Tuesday January 25 2021

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Day Two

Wednesday, January 26 2022

3:30 pm | DDRi R&D in CNS Tumors: Landscape & Opportunities

Tatjana Stankovic
Institute of Cancer and Genomic Sciences
University of Birmingham

Day Two

Wednesday, January 26 2022

4:30 pm | Understanding Connections Between Immune Response & DNA Damage Defects in Chronic Lymphocytic Leukaemia ( CLL) as a Disease Model

Katie Pawelczak
VP of Research
NERx Biosciences

Day Two

Wednesday, January 26 2022

11:30 am | Targeting Protein-DNA Interactions in the DNA Damage Response: Lead Identification & Optimization for Novel Inhibitors of Replication Protein A (RPA) & Ku

Sotirios Sotiriou
Head of Biology & Co-Founder
FoRx Therapeutics

Day Two

Wednesday, January 26 2022

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

John Pollard
Chief Scientific Officer
Dark Blue Therapeutics

Eytan Ruppin
Chief - Cancer Data Science Lab
National Cancer Institute

Day Two

Wednesday, January 26 2022

10:00 am | Synthetic Lethality-Mediated Precision Oncology

Wael Jdey
Lead Scientist
Onxeo

Day Two

Wednesday, January 26 2022

9:30 am | Drug-driven HRD: From Bench to Bedside & Back: Discovering Novel Biomarkers for PARP

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

Daniel Speidel
Managing Director & Co-Founder
Breakpoint Therapeutics

Day Two

Wednesday, January 26 2022

5:30 pm | Closing Panel Discussion: Future Directions for DDRi

Graeme Smith
Chief Scientific Officer
Artios Pharmaceuticals

Day Two

Wednesday, January 26 2022

7:50 am | Chair’s Opening Remarks

Michael Zinda
Chief Scientific Officer, Executive Vice President, Head of Research & Development
Repare Therapeutics

Arne Nedergaard
Kousholt Postdoctoral Researcher
Jos Jonkers Group, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute

Asli Muvaffak
Associate Director - Scientific, Oncology, Synthetic Lethality & Research Unit
GSK

Laure Escoubet
Vice President, Discovery Biology
Zentalis Pharmaceuticals

Day One

Tuesday January 25 2021

8:00 am | Chair’s Opening Remarks

Asima Mukhopadhyay
Gynaecological Oncologist & Clinician Scientist,
Chittaranjan National Cancer Institute India & Newcastle University

Day Two

Wednesday, January 26 2022

3:00 pm | Durability of PARP Inhibition: Implications for Dose & Schedule as Single Agent & Combination Therapy

Jennifer Molina
Principal Scientist
Ribon Therapeutics

Day One

Tuesday January 25 2021

9:00 am | Inhibition of PARP7 by RBN-2397 Activates the Type I Interferon Response in Tumors Leading to Robust Antitumor Activity